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The introduction of 5HT3-receptor antagonists has meant a break-
through in the protection against chemotherapy-induced acute
emesis (Verweij et al, 1996). When combined with dexametha-
sone, 5HT3-receptor antagonists result in complete protection in
70–80% of patients receiving highly emetogenic chemotherapy
(Gandara et al, 1998). The 2 most widely used agents are
ondansetron (Zofran) and granisetron (Kytril). In Europe, the
approved dose of ondansetron is 8 mg i.v., and of granisetron 3 mg
i.v., both given as a single dose, prior to the administration of the
chemotherapy (Kamanabrou, 1992; Gandara et al, 1998). Several
trials comparing 5HT3-receptor antagonists have demonstrated
equivalent anti-emetic efficacy (Ruff et al, 1994; Navari et al,
1995; Stewart et al, 1995; Perez et al, 1998). In view of the simi-
larity in chemical structure these agents act at the same receptor,
and it is assumed that failure to one 5HT3-receptor antagonists
would predict subsequent failure to all 5HT3-receptor antagonists
(Verweij et al, 1996; Gandara et al, 1998; Gralla, 1998). In a pilot
experience we previously observed successful protection after
crossing over between 5HT3-receptor antagonists (De Boer et al,
1995). In that uncontrolled pilot study several patients who had
acute emesis protection failure on tropisetron were completely
protected after cross-over to ondansetron. The present report
involves a randomized double blind cross-over study of
granisetron plus dexamethasone versus continued treatment with
ondansetron plus dexamethasone, in patients with protection
failure on ondansetron plus dexamethasone during the first 24
hours following highly emetogenic chemotherapy. 
PATIENTS AND METHODS 
Eligibility required protection failure (defined as ≥ 2 vomits,
severe nausea (no significant intake possible) or nausea > 4 hours)
within 24 hours after single day cisplatin ≥ 50 mg m–2 or
cyclophosphamide  ≥ 500 mg m–2 based chemotherapy, on
antiemetic prophylaxis with ondansetron 8 mg i.v. and dexametha-
sone 10 mg i.v. Eligibility also required that there were no planned
dose attenuations, no use of other antiemetic agents, benzo-
diazepines, or opiates, and no emesis in the 24 hours preceding
the study cycle. 
After informed consent patients were randomized in a double
blind fashion to granisetron 3 mg i.v. plus dexamethasone 10 mg
i.v. or continued treatment with ondansetron 8 mg i.v. plus dexam-
ethasone 10 mg i.v. The medication was prepared in blinded 50 ml
saline bags by the pharmacist. 
Results were documented by the patient on diary cards: 
  Complete protection (CP) was defined as no vomiting and no
or mild nausea. 
  Partial protection (PP) was defined as 0–1 vomits, and/or
moderate nausea during a maximum of 4 hours. 
  Failure (F) was defined as ≥ 2 vomits, or severe nausea (no
significant intake possible), or nausea lasting more than 4
hours. 
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Summary In view of the similarity in chemical structure of the available 5HT3-receptor antagonists it is assumed, whilst these agents all act at
the same receptor, that failure to one agent would predict subsequent failure to all 5HT3-receptor antagonists. We conducted a randomized
double blind trial of granisetron 3 mg plus dexamethasone 10 mg versus continued treatment with ondansetron 8 mg plus dexamethasone
10 mg in patients with protection failure on ondansetron 8 mg plus dexamethasone 10 mg during the first 24 hours following highly
emetogenic chemotherapy. Of 40 eligible patients, 21 received ondansetron + dexamethasone and 19 received granisetron
+ dexamethasone. We found a significant benefit from crossing-over to granisetron after failure on ondansetron. Of the 19 patients who
crossed over to granisetron, 9 patients obtained complete protection, whereas this was observed in 1 of the 21 patients continuing
ondansetron, P = 0.005. These results indicate that there is no complete cross-resistance between 5HT3-receptor antagonists, and that
patients who have acute protection failure on one 5HT3-receptor antagonist should be offered cross-over to another 5HT3-receptor antagonist.
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A total of 45 patients were randomized. 5 patients were excluded
at the study cycle for the following reasons; nausea prior to the
chemotherapy (2), chemotherapy dose reductions (2), other
antiemetics (1). Of 40 eligible patients, 21 received ondansetron
plus dexamethasone, and 19 crossed-over to granisetron plus
dexamethasone. Patients were well balanced for age, sex, type and
dose of chemotherapy and number of previous cycles (Table 1). 
We found a significant benefit from crossing-over to granisetron
after failure to ondansetron (Table 2). Of the 19 patients who
crossed-over to granisetron, 9 patients obtained complete protec-
tion (CP), whereas this was observed in 1 of 21 patients continuing
ondansetron, P = 0.005 (Fisher exact test). The P value of a test for
trend with ordered categories (χ 2 trend) was < 0.005. Successful
cross-over was observed both in patients receiving cisplatin, and in
patients receiving cyclophosphamide-based chemotherapy, but the
numbers in the subsets were too small to perform meaningful
subanalyses. 
DISCUSSION 
Several large well-designed randomized studies between
ondansetron and granisetron have demonstrated equivalent
antiemetic efficacy (Ruff et al, 1994; Navari et al, 1995; Stewart
et al, 1995; Perez et al, 1998). Reviewing the more recently
conducted randomized trials of a sample size that justifies to draw
such conclusion, there appears no therapeutical difference between
ondansetron doses ranging from 8 mg, given as a single dose
before the start of the chemotherapy to 32 mg administered during
the first 24 hours (Ruff et al, 1994; Italian Group of Antiemetic
Research, 1995; Gandara et al, 1998). The same applies for
granisetron single dosages of 1 and 3 mg (Navari et al, 1994, 1995;
Morrow et al, 1995; Perez et al, 1997; Gralla, 1998; Martoni et al,
1998). In addition, there are no data to support the use of higher
doses of the same 5HT3-receptor antagonists in patients failing the
recommended dosage (Gandara et al, 1998). 
Hence, it is unlikely that the high rate of successful complete
protection by granisetron after failure to ondansetron in the present
study can be explained by better dose-effectiveness of granisetron
3 mg as compared with ondansetron 8 mg. The results in our study
indicate that there is no complete cross-resistance between these
two 5HT3-receptor antagonists, at least not in the sequence
ondansetron failure, followed by cross-over to granisetron. These
findings lend support to our previous observation of successful
cross-over between 5HT3 receptor antagonists, indicating that
there is no complete cross-resistance between those agents (de
Boer et al, 1995). In this pilot study, 5 of 14 patients who had
emesis protection failure on tropisetron obtained complete protec-
tion after cross-over to ondansetron. 
Therefore, we conclude that there is no cross-resistance
between 5HT3-receptor antagonists and that patients who have
acute protection failure on one 5HT3-receptor antagonist should be
offered cross-over to another 5HT3-receptor antagonist. 
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Table 1 Patient characteristics (eligible patients) 
Granisetron Ondansetron  
(n = 19) (n = 21)
Sex female/male 18/1 18/3 
Median age (range) 46 (29–71) 46 (30–73) 
Cisplatin-based chemotherapy 7 6 
Cyclophosphamide-based chemotherapy 12 15 
Previous cycles (number + range) 2 (2–15) 2 (2–13) 
Tumour type 
Breast 11 14 
Ovarian 3 1 
Lung 2 2 
Other 3 4 
Table 2 Results after cross-over 
Cisplatin-based  Complete protection Partial protection Failure 
chemotherapy
Ondansetron (n = 6) 0 2 4 
Granisetron (n = 7) 2 2 3 
Cyclophosphamide-based  Complete protection Partial protection Failure 
chemotherapy
Ondansetron (n = 15) 1 3 11 
Granisetron (n = 12) 7 2 3 
Total Complete protection Partial protection Failure 
Ondansetron (n = 21) 1 6 14 
Granisetron (n = 19) 9* 3 7 
*Fisher exact test (Complete Protection vs no Complete Protection), 
P = 0.005, χ 2 test for trend, P < 0.001. intravenous granisetron infusion and a standard (15-minute) intravenous
ondansetron infusion in breast cancer patients receiving moderately emetogenic
chemotherapy. Cancer J Sci Am 4: 52–58 
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